Cognitive function during ECT in young adults with TRD
Examining the clinical features and cognitive outcomes of young adults with treatment-resistant depression undergoing electroconvulsive therapy. Read more
Source: dovepress.com
📰 Rating Scale News
Page 4 - Rating Scale News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rating Scale. Real-time updates on events, politics, business and more.
EWZS ETF: Just Small Enough To Fall Under The Populist Radar
IShares MSCI Brazil Small-Cap ETF tracks an index of Brazilian small-cap stocks. See why we believe EWZS ETF is too volatile that we rate it a Sell here.
Source: seekingalpha.com
ASEA: The Dragon Next Door Keeps This Fund From Delivering On Its Promise
Global X FTSE Southeast Asia ETF (ASEA) tracks an index of the 40 largest stocks from Southeast Asia. See why we rate the fund a hold for the short term.
Alex Rosen Bank Singapore Bank Central Asia Association Of Southeast Asian Nations Group Holdings Ltd United Overseas Bank Singapore
Source: seekingalpha.com
BWX ETF : Finally Deserves A Look As 2 Mega-Trends Reverse
SPDR Bloomberg Barclays International Treasury Bond Fund is a fund investors could be excused for ignoring since at least 2018. See why BWX ETF is a buy now.
United States United Kingdom Rob Isbitts Bloomberg Barclays International Treasury Bond European Central Bank Us Congress
Source: seekingalpha.com
AAXJ ETF: This Could Be A Fund To Really Get Behind
IShares MSCI All Country Asia ex-Japan Fund provides exposure to mid and large cap companies in Asia. See why we rate AAXJ ETF a Hold for now.
Source: seekingalpha.com
Investegate |Clinigen Announcements | Clinigen: Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis
Investegate announcements from Clinigen, Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis
Source: investegate.co.uk
Clinigen notes results from the MIROCALS trial investigating low dose Proleukin (aldesleukin) in patients with amyotrophic lateral sclerosis
8 December 2022 Clinigen notes results from the MIROCALS trial investigating low dose Proleukin (aldesleukin) in patients with amyotrophic lateral sclerosis Clinigen Limited
Source: finanznachrichten.de
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Source: prnewswire.com
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
United States University Of Massachusetts Medical School John Mullaly Anthony Windebank Robert Brown Namita Goyal
Source: prnewswire.com
Tofersen Fails to Improve Motor Functions in Patients With SOD1 ALS
Tofersen alone does not significantly change function in patients with faster progressing SOD1 amyotrophic lateral sclerosis.
Source: neurologyadvisor.com